



LONG TERM SUBSCRIBE

IPO Report

24th Mar'26

Snapshot

Company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. Company is in the business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets. Company’s portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, company have capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampoules, and vials.

VALUATION

Company is bringing the issue at price band of Rs 372-392 per share at p/e multiple of more than 70x on post issue annualized H1FY26 PAT basis.

Company is diversified generic formulations player with an established track record . Company has strategically located and accredited Manufacturing Facilities . Also, company has strong focus on CDMO business. Company has well-established sales network in India and overseas with Track record of value-accretive acquisitions & experienced Promoters and Senior Management with extensive domain knowledge Hence, we recommend “Long term Subscribe” to issue.

Price Band (Rs./Share)	372-392
Opening date of the issue	24 th Mar '2026
Closing Date of the issue	27 th Mar '2026
No of shares pre issue	3,69,08,823 Eq Shares
Issue Size	Rs 402-409 Cr
Offer For Sale	3,157,880 Eq Shares
Fresh issue	Rs 285 Cr
Face Value (Rs/ share)	Rs 5/share
Bid Lot	38

BIDDING DETAILS

QIBs (Including Anchor)	50% of the offer (Approx 52,14,143 eq Shares)
Non-Institutional	15% of the offer (Approx 15,64,244 eq Shares)
Retail	35% of the offer (Approx 36,49,901 eq Shares)
Lead managers	Arihant Capital Markets Ltd
Registrar to the issue	Bigshare Services Pvt. Ltd

WHAT WE LIKE

Diversified generic formulations player with an established track record

Company was incorporated in 2001 and initially focused on manufacturing parenteral (injectables) formulations, reporting annual revenue of around ₹8.6 million by the time the current management assumed leadership in 2016. Since then, Company has undergone a steady expansion across business verticals, geographical markets, and customer segments and achieved revenue of operations of ₹1,631.05 million in Fiscal 2025. This growth has been driven by operational efficiency and strategic diversification of product offerings and consistent focus on strengthening company’s market presence.

Strong focus on CDMO business.

Company commenced engagements with domestic CDMO customers in Fiscal 2022 and expanded company’s CDMO operations to international markets in Fiscal 2023, supported by the acquisition of two internationally accredited Manufacturing Facilities i.e. Unit III and IV which enabled company’s entry into the Regulated and Semi-Regulated Markets. These acquisitions not only expanded company’s product portfolio but also led to establishment of a dedicated FR&D facility enhancing its ability to deliver end-to-end development and technical services. The acquisition of Noumed will further strengthen company’s CDMO business, particularly in the OTC segment.

Well-established distribution network in India and overseas

Company have an established presence in the institutional markets, supported by the experience of its promoters and company’s wholly owned subsidiary, Revat Laboratories. Company’s institutional business spans multiple Indian states, contributing to growing visibility and recognition within this segment. Company participate in procurement tenders issued by central and state government agencies for the supply of both high-value and high-volume pharmaceutical formulations. Company supply to various state procurement agencies, as well as to multiple locations under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) and ESI hospitals across India.



COMPANY BACKGROUND

Company manufacture and sell Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market. Company started its export business in Fiscal 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. Company export its products to the Regulated and Semi-Regulated Markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through distributors.

Company's CDMO business includes product development, which involves designing and developing new pharmaceutical products, validation batches i.e. trial runs conducted to ensure consistent manufacturing quality, stability studies, which assess drug performance under various conditions, dossier compilation, which involves preparing and compiling documents required for product approvals, international regulatory filings which involves submission to regulatory authorities in a particular jurisdiction to register or sell a drug/medicine and commercial manufacturing. Company's R&D and regulatory compliance capabilities positions company as a reliable CDMO partner for its customers in the Regulated and Semi-Regulated Markets. Company, through its wholly owned Singapore subsidiary, Sai Parenterals Pte Limited ("**Buyer**"), entered into a Share Purchase Agreement dated September 24, 2025 with Noumed Life Sciences Limited (UK) ("**NLS**") ("**Seller**"), Mark Thulborne, Jo-maree Delac. Due to certain changes in payment milestones, the parties executed a fresh Share Purchase Agreement dated October 24, 2025 ("**SPA**"). The SPA has been entered into to acquire a 74.60% majority and controlling stake in Noumed, including an equity infusion of AUD 4.00 million as a primary in Noumed Pharmaceuticals Pte Ltd, Australia. Noumed Pharmaceuticals Pty Limited ("**Noumed**"), an Australia-based pharmaceutical company engaged primarily in the business of supplying OTC pharmaceutical products to retail pharmacy chains in Australia. Noumed also operates in New Zealand through its wholly owned subsidiary, Noumed Pharmaceuticals Limited, offering both prescription ("**Rx**") and OTC products, with a focus on securing government procurement contracts through Pharmaceutical Management Agency ("**Pharmac**") tenders. The entire share transfer and issue of fresh equity shares in Noumed has been completed on November 12, 2025.

OBJECTS OF OFFER

The Offer comprises a Fresh Issue by Company and Offer for Sale by the Promoter Selling Shareholders.

Objects of Fresh Issue

Company proposes to utilise the Net Proceeds towards funding of the following objects:

1. Capacity expansion and upgradation of manufacturing facilities;
2. Establishment of a new R&D Centre;
3. Repayment / prepayment of certain outstanding borrowings;
4. Working capital requirements;
5. Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and

RISKS

Company's manufacturing facilities are concentrated in Hyderabad, Telangana and Ongole, Andhra Pradesh. Company is exposed to risks originating from slowdown or shutdown, economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect company's business, results of operations and financial condition.

Source:RHP



Consolidated Financials

(Rs in Mn)

Financials	FY23	FY24	FY25	H1FY26
Total Revenue (A)	967.96	1537.61	1631.06	869.18
Total Expenditure (B)	791.72	1221	1237.21	707.52
EBIDTA	176.24	316.61	393.85	161.66
EBIDTA Margin	18.21	20.59	24.15	18.60
Other Income	2.32	14.19	6.38	25.09
Depreciation	57.93	94.18	82.04	28.85
EBIT	120.63	236.62	318.19	157.90
Interest	48.13	111.07	119.10	46.31
PBT	72.50	125.55	199.09	111.59
Share of profit in Asso	0.00	0.00	0.00	0.00
PBIT	72.50	125.55	199.09	111.59
Exceptional	0.00	0.00	0.00	0.00
PBT	72.50	125.55	199.09	111.59
Tax	28.75	41.40	54.82	33.94
PAT	43.75	84.15	144.27	77.65
NPM	4.52	5.47	8.85	8.93
ROE%	13.90	11.01	15.09	5.13
EPS	6.16	10.54	5.43	2.82
Eq Cap	71.51	132.48	133.09	184.54
Net Worth	314.86	764.01	957.79	2,093.71

(Source: RHP)



DISCLAIMER

HEM Securities Limited ("Research Entity or HSL") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services, merchant banking services, Portfolio Management Services and other related activities. Broking services offered by HEM Securities Limited are under SEBI Registration No.: INZ000168034.

This Report has been prepared by HEM Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH100002250 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. This should not be construed as invitation or solicitation to do business with HSL. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject HSL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. HSL reserves the right to make modifications and alterations to this statement as may be required from time to time. HSL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. HSL is committed to providing independent and transparent recommendation to its clients. Neither HSL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

HSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.